Issue 4 - August 2010 - Pacini Editore

150
16 Kipp BR, Tyner HL, Campion MB, et al. Chromosomal alterations
detected by fluorescence in situ hybridization in urothelial carcinoma
and rarer histologic variants of bladder cancer. Am J Clin Pathol
2008;130:552-9.
17 Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TM-
PRSS2 and ETS transcription factor genes in prostate cancer. Science
2005;310:644-8.
18 Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion
associated with lethal prostate cancer in a watchful waiting cohort.
Oncogene 2007;26:4596-9.
19 Saramaki OR, Harjula AE, Martikainen PM, et al. TMPRSS2:ERG
fusion identifies a subgroup of prostate cancers with a favorable prognosis.
Clin Cancer Res 2008;14:3395-400.
20 Stapleton AM, Zbell P, Kattan MW, et al. Assessment of the biologic
markers p53, Ki-67, and apoptotic index as predictive indicators of
prostate carcinoma recurrence after surgery. Cancer 1998;82:168-75.
21 Brewster SF, Oxley JD, Trivella M, et al. Preoperative p53, bcl-2,
CD44 and E-cadherin immunohistochemistry as predictors of biochemical
relapse after radical prostatectomy. J Urol 1999;161:1238-
43.
22 Stackhouse GB, Sesterhenn IA, Bauer JJ, et al. p53 and bcl-2 immunohistochemistry
in pretreatment prostate needle biopsies to predict
recurrence of prostate cancer after radical prostatectomy. J Urol
1999;162:2040-5.
23 Vis AN, van Rhijn BW, Noordzij MA, et al. Value of tissue markers
p27(kip1), MIB-1, and CD44s for the pre-operative prediction
of tumour features in screen-detected prostate cancer. J Pathol
2002;197:148-54.
24 Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG,
AR and PTEN gene status in circulating tumor cells from patients with
castration-resistant prostate cancer. Cancer Res 2009;69:2912-8.
25 Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates
with loss of PTEN to promote cancer progression in the prostate.
Nat Genet 2009;41:619-24.
26 Gravina GL, Biordi L, Martella F, et al. Epigenetic modulation of
PTEN expression during antiandrogenic therapies in human prostate
cancer. Int J Oncol 2009;35:1133-9.
27 King JC, Xu J, Wongvipat J, et al. Cooperativity of TMPRSS2-ERG
with PI3-kinase pathway activation in prostate oncogenesis. Nat
Genet 2009;41:524-6.
28 Yoshimoto M, Cutz JC, Nuin PA, et al. Interphase FISH analysis of
PTEN in histologic sections shows genomic deletions in 68% of primary
prostate cancer and 23% of high-grade prostatic intra-epithelial
neoplasias. Cancer Genet Cytogenet 2006;169:128-37.
29 Schmitz M, Grignard G, Margue C, et al. Complete loss of PTEN
expression as a possible early prognostic marker for prostate cancer
metastasis. Int J Cancer 2007;120:1284-92.
30 Diaz JI, Mora LB, Austin PF, et al. Predictability of PSA failure in
prostate cancer by computerized cytometric assessment of tumoral cell
proliferation. Urology 1999;53:931-8.
31 Bostwick DG, Wheeler TM, Blute M, et al. Optimized microvessel
density analysis improves prediction of cancer stage from prostate
needle biopsies. Urology 1996;48:47-57.
32 Khan MA, Walsh PC, Miller MC, et al. Quantitative alterations in
nuclear structure predict prostate carcinoma distant metastasis and
death in men with biochemical recurrence after radical prostatectomy.
Cancer 2003;98:2583-91.
33 Gettman MT, Bergstralh EJ, Blute M, et al. Prediction of patient
outcome in pathologic stage T2 adenocarcinoma of the prostate: lack
of significance for microvessel density analysis. Urology 1998;51:79-
85.
34 Zhang YH, Kanamaru H, Oyama N, et al. Prognostic value of nuclear
morphometry on needle biopsy from patients with prostate cancer: is
volume-weighted mean nuclear volume superior to other morphometric
parameters? Urology 2000;55:377-81.
35 Lapointe J, Li C, Higgins JP, van de Rijn M, et al. Gene expression
profiling identifies clinically relevant subtypes of prostate cancer.
Proc Natl Acad Sci USA 2004;101:811-6.
36 Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals
alternative genetic pathways of prostate tumorigenesis. Cancer Res
2007;67:8504-10.
37 Jones TD, Ulbright TM, Eble JN, et al. OCT4 staining in testicular
tumors: a sensitive and specific marker for seminoma and embryonal
carcinoma. Am J Surg Pathol 2004;28:935-40.
38 Looijenga LH, Stoop H, de Leeuw HP, et al. POU5F1 (OCT3/4)
5 th triennial congress of the italian society of anatomic Pathology and diagnostic cytoPathology
identifies cells with pluripotent potential in human germ cell tumors.
Cancer Res 2003;63:2244-50.
39 Manivel JC, Jessurun J, Wick MR, et al. Placental alkaline phosphatase
immunoreactivity in testicular germ-cell neoplasms. Am J Surg
Pathol 1987;11:21-9.
40 Suster S, Moran CA, Dominguez-Malagon H, et al. Germ cell tumors
of the mediastinum and testis: a comparative immunohistochemical
study of 120 cases. Hum Pathol 1998;29:737-42.
41 Leroy X, Augusto D, Leteurtre E, et al. CD30 and CD117 (c-kit) used
in combination are useful for distinguishing embryonal carcinoma
from seminoma. J Histochem Cytochem 2002;50:283-5.
42 Cheville JC, Rao S, Iczkowski KA, et al. Cytokeratin expression in
seminoma of the human testis. Am J Clin Pathol 2000;113:583-8.
43 de Jong J, Stoop H, Gillis AJ, et al. Differential expression of SOX17
and SOX2 in germ cells and stem cells has biological and clinical
implications. J Pathol 2008;215:21-30.
44 Eglen DE, Ulbright TM. The differential diagnosis of yolk sac tumor
and seminoma. Usefulness of cytokeratin, alpha-fetoprotein, and
alpha-1-antitrypsin immunoperoxidase reactions. Am J Clin Pathol
1987;88:328-32.
45 Hersmus R, de Leeuw BH, Wolffenbuttel KP, et al. New insights into
type II germ cell tumor pathogenesis based on studies of patients with
various forms of disorders of sex development (DSD). Mol Cell Endocrinol
2008;291:1-10.
46 Cools M, Drop SL, Wolffenbuttel KP, et al. Germ cell tumors in the
intersex gonad: old paths, new directions, moving frontiers. Endocr
Rev 2006;27:468-84.
47 Krausz C, Degl’Innocenti S. Y chromosome and male infertility: update,
2006. Front Biosci 2006;11:3049-61.
48 Krausz C, Giachini C. Genetic risk factors in male infertility. Arch
Androl 2007;53:125-33.
49 Meng FJ, Zhou Y, Giwercman A, et al. Fluorescence in situ hybridization
analysis of chromosome 12 anomalies in semen cells from patients
with carcinoma in situ of the testis. J Pathol 1998;186:235-9.
50 Oosterhuis JW, Looijenga LH. Testicular germ-cell tumours in a
broader perspective. Nat Rev Cancer 2005;5:210-22.
51 Cheng L, Zhang S, MacLennan GT, et al. Interphase fluorescence in
situ hybridization analysis of chromosome 12p abnormalities is useful
for distinguishing epidermoid cysts of the testis from pure mature
teratoma. Clin Cancer Res 2006;12:5668-72.
52 Kernek KM, Brunelli M, Ulbright TM, et al. Fluorescence in situ hybridization
analysis of chromosome 12p in paraffin-embedded tissue
is useful for establishing germ cell origin of metastatic tumors. Mod
Pathol 2004;17:1309-13.
53 Yamaguchi S, Yoshihiro S, Matsuyama H, et al. The allelic loss of
chromosome 3p25 with c-myc gain is related to the development of
clear-cell renal cell carcinoma. Clin Genet 2003;63:184-91.
54 Brunelli M, Eble JN, Zhang S, et al. Gains of chromosomes 7, 17, 12,
16, and 20 and loss of Y occur early in the evolution of papillary renal
cell neoplasia: a fluorescent in situ hybridization study. Mod Pathol
2003;16:1053-9.
55 Tickoo SK, dePeralta-Venturina MN, Harik LR, et al. Spectrum of
epithelial neoplasms in end-stage renal disease: an experience from
66 tumor-bearing kidneys with emphasis on histologic patterns distinct
from those in sporadic adult renal neoplasia. Am J Surg Pathol
2006;30:141-53.
56 Gobbo S, Eble JN, Grignon DJ, et al. Clear Cell Papillary Renal Cell
Carcinoma: A Distinct Histopathologic and Molecular Genetic Entity.
Am J Surg Pathol 2008 in press.
57 Cossu-Rocca P, Eble JN, Delahunt B, et al. Renal mucinous tubular
and spindle carcinoma lacks the gains of chromosomes 7 and 17 and
losses of chromosome Y that are prevalent in papillary renal cell carcinoma.
Mod Pathol 2006;19:488-93.
58 Srigley J. Mucinous tubular and spindle cell carcinoma. In: Eble JN,
Sauter G, Epstein JI, Sesterhenn IA (eds). World Health Organization
Classification of Tumours: Pathology and Genetics of Tumours of the
Urinary System and Male Genital Organs. Lyon: IARC Press 2004,
p. 40.
59 Renshaw AA, Maurici D, Fletcher JA. Cytologic and fluorescence
in situ hybridization (FISH) examination of metanephric adenoma.
Diagn Cytopathol 1997;16:107-11.
60 Brunelli M, Eble JN, Zhang S, et al. Metanephric adenoma lacks
the gains of chromosomes 7 and 17 and loss of Y that are typical of
papillary renal cell carcinoma and papillary adenoma. Mod Pathol
2003;16:1060-3.